1. Cobo F, Concha A, Ortiz M. Human papillomavirus type distribution in females with abnormal cervical cytology; a correlation with histological study. Open Virol J. 2009;3:60–6.
2. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of pre-cancerous and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol. 2007;109:1325–31.
3. Wong CA, Berkowitz Z, Dorell CG, Anhang Price R, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9-to 17-year-old girls. National Health Interview Survey 2008Cancer. 2011;117:5612–20.
4. Mu˜ noz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl. 3):1–10.
5. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection:unresolved issues. Nat Rev Cancer. 2007;7:11–22.
6. Denny L. Human papilloma virus in gynaecology. Best Practice Research Clinical Obstetrics Gynaecology. 2018;47:1.
7. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.
8. Crow JM. HPV: the global burden. Nature 2012;488(7413).
9. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases, Vaccine. 2012;30:F12–23.
10. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related health-care utilization among privately insured patients in the United States[J]. Sex Transm Dis. 2004;31(12):748–52.
11. Psyrri A, Dimaio D. Human papillomavirus incervical and head and neck canner[J]. Nat Clin Pract Oncol. 2008;5(1):24–31.
12. Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17:1611–22.
13. Mejlhede N, Pedersen BV, Frisch M, et al. Multiple human papilloma virus types in cervical infections: competition or synergy? APMIS. 2010; 118:346–352.
14. Pirog EC, Chen YT, Isacson C. MIB-1 immunostaining is a beneficial adjunct test for accurate diagnosis of vulvar condyloma acuminatum. Am J Surg Pathol. 2000;24:1393–9.
15. Wiley DJ, DouglasJ BeutnerK, et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis. 2002;35(Suppl. 2):210-24.
16. Fairley CK, Donovan B. What can surveillance of genital warts tell us? Sex Health. 2010;7:325.
17. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of noncancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24:35–41.
18. Li-hua LU, Jing YU, Yin-han, ZHANG,et al. HPV Infection and Distribution of HPV Genotypes on Patients with Condyloma Acuminatum. Journal of Reproduction Contraception. 2014;25(1):26–31.
19. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–85.
20. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125:2151–8.
21. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, et al. EpidemiolOgy and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26:K1–16.
22. Krzowska-Firych J, Georgia L, Christiana L, et al. An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. J Infect Public Health. 2019;12(1):1–6.
23. Sohrabi A, Hajia M, Jamali F, Kharazi F, et al. Is incidence of multiple HPV genotypes rising in genital infections? J Infect Public Health. 2017;10(6):730–3.
24. Lee SH, Kan GD. Mutiple HPV infection in cervical cancer screened by HPV DNA chip[J].Cancer Letter,2003,198(2):187–192.
25. Ho GY, Bierman R, Bearsley L,et al. Natural history of cervicovaginal papillomavirus infection in young women[J]. N EngI J Med. 1998;338(7):423–8.
26. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl). 2004;193:35–44.
27. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.Vaccine 2008, 26(Suppl 10):K17-K28.
28. Blomberg M, Friis S, Munk C,et al.Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts.J Infect Dis,2012((205):1544–1553.
29. Arima Y, Winer RL, Feng Q,et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis. 2010;202(8):1181–4.
30. Baloch Z, Yuan T, Wang B, Tai W, Feng Y, Liu Y, et al. Ethnic and geographic variations in HPV prevalence and genotype distribution in north-western Yunnan,China. J Med Virol. 2016;88(3):532–40.
31. Gravitt PE, Rositch AF, Silver MI, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States[J]. J Infect Dis. 2013;207(2):272–80.
32. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide[J]. Int J Cancer,2006,119(11):2677–2684.
33. Hawkins MG, et al. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J. 2013;10:137.